Cellebrite DI Ltd.
CLBT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | 0.12 | 0.24 | 0.01 |
| FCF Yield | 2.63% | 5.72% | 1.44% | 2.42% |
| EV / EBITDA | 65.68 | -22.71 | 70.74 | 11.23 |
| Quality | ||||
| ROIC | 14.47% | 12.01% | 0.52% | 7.83% |
| Gross Margin | 84.40% | 83.63% | 81.25% | 82.72% |
| Cash Conversion Ratio | -0.47 | -1.26 | 0.17 | 0.50 |
| Growth | ||||
| Revenue 3-Year CAGR | 14.02% | 9.70% | 11.56% | 12.74% |
| Free Cash Flow Growth | 29.13% | 719.18% | -58.87% | -53.69% |
| Safety | ||||
| Net Debt / EBITDA | -2.68 | 2.71 | -7.06 | -1.62 |
| Interest Coverage | 0.16 | 235.72 | 0.01 | 24.51 |
| Efficiency | ||||
| Inventory Turnover | 7.00 | 5.36 | 4.99 | 6.54 |
| Cash Conversion Cycle | 62.46 | 98.12 | 146.24 | 74.03 |